Inozyme Pharma rises on complete enrolment for genetic disorder drug trials

Inozyme Pharma

08/12/2022 17:57

** Shares of Inozyme Pharma Inc  INZY.O  up 6.2% at $1.54
    ** Co says it has fully enrolled patients in dose escalation
portion of its early- to mid-stage trials for experimental drug
INZ-701, according to regulatory filing
    ** The drug is being tested for rare genetic disorders such
as ENPP1 and ABCC6 deficiencies
    ** Co plans to report topline data from trials in Q1 2023
    ** Including session's moves, stock down ~77% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))